Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1

AIM: The mTOR-inhibitor rapamycin has shown antitumor activity in various tumors. Bedside observations have suggested that rapamycin may be effective as a treatment for colorectal carcinomatosis. METHODS: We established an orthotopic syngenic model by transplanting CT26 peritoneal tumors in Balb/C mice and an orthotopic xenograft model by transplanting SW620 peritoneal tumors in nu/nu mice. Expression levels of tissue inhibitor of matrix-metalloproteinases 1 (TIMP-1) in the tumor and serum was determined by enzyme-linked immunosorbent assay. RESULTS: Rapamycin significantly suppressed growth of syngenic and xenografted peritoneal tumors. The effect was similar with intraperitoneal or oral rapamycin administration. Tumor suppression was further enhanced when rapamycin was combined with 5-fluorouracil and/or oxaliplatin. The combination treatment showed no acute toxicity. TIMP-1 serum levels correlated well (CC = 0.75; P < 0.01) with rapamycin treatment. CONCLUSIONS: Rapamycin suppressed advanced stage colorectal cancer, even with oral administration. Combining rapamycin with current chemotherapy regimens significantly increased antitumor efficacy without apparent toxicity. The treatment efficacy correlated with serum TIMP-1 levels, suggesting its potential as a surrogate marker in future clinical trials.

Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients

BACKGROUND: Chemotherapies of solid tumors commonly include 5-fluorouracil (5-FU). With standard doses of 5-FU, substantial inter-patient variability has been observed in exposure levels and treatment response. Recently, improved outcomes in colorectal cancer patients due to pharmacokinetically guided 5-FU dosing were reported. We aimed at establishing a rapid and sensitive method for monitoring 5-FU plasma levels in cancer patients in our routine clinical practice. METHODS: Performance of the Saladax My5-FU™ immunoassay was evaluated on the Roche Cobas® Integra 800 analyzer. Subsequently, 5-FU concentrations of 247 clinical plasma samples obtained with this assay were compared to the results obtained by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and other commonly used clinical analyzers (Olympus AU400, Roche Cobas c6000, and Thermo Fisher CDx90). RESULTS: The My-FU assay was successfully validated on the Cobas Integra 800 analyzer in terms of linearity, precision, accuracy, recovery, interference, sample carryover, and dilution integrity. Method comparison between the Cobas Integra 800 and LC-MS/MS revealed a proportional bias of 7% towards higher values measured with the My5-FU assay. However, when the Cobas Integra 800 was compared to three other clinical analyzers in addition to LC-MS/MS including 50 samples representing the typical clinical range of 5-FU plasma concentrations, only a small proportional bias (≤1.6%) and a constant bias below the limit of detection was observed. CONCLUSIONS: The My5-FU assay demonstrated robust and highly comparable performance on different analyzers. Therefore, the assay is suitable for monitoring 5-FU plasma levels in routine clinical practice and may contribute to improved efficacy and safety of commonly used 5-FU-based chemotherapies.

Replica ai pareri del rabbino J. Costa e di altri rabbini sulla validità del testamento del fu conte Caid Nissim Samama

[David Castelli]

Parere : [sulla validità, secondo la legge ebraica, del testamento del fu Caid Nissim Samama]

[David Castelli]

Guarantie-Schein von acht gesessenen Bürgerlichen Deputirten, die Einkünffte der Stadt auff hundert tausend Gülden jährlichen Einkünfften, auff den Fuß, wie sie Magistratus bißher erhebt, gleich in primo anno weiter und hernach viel höher zuverrechnen : In Causa Commissionis Impetrantischer Bürgerschafft der Kayserl. Freyen Reichs- auch Wahl- und Crönungs-Stadt Franckfurth Contra E. E. Rath allda ; Ihro Röm. Kayserl. Majestät benebenst einem allerunterthänigsten Memorial sub lit. B originaliter ... den 28. Jan. 1715 ... überreicht

[David Düring, Peter Bischoff, Johannes Klotz, Johann Conrad Siegling, Paul Hennrici, David Klotz, Joh. Dietrich Notebohm, Joachim Hoppe] [[Elektronische Ressource]]

Der "Stuhl des Moses" im jüdischen Tempel von Kai-feng-fu [Illustration] : Aus Sigm. Feist: Stammeskunde der Juden

Scan von Monochrom-Mikroform

Giuseppina Strepponi als Nina, Rollenbild, Hüftbild, in: Giovanni Paisiello: Nina o sia la pazza per amore : Nina: T'amo, fu il primo accento Che disse a te il mio core,

Signatur des Originals: S 36/G04409